Castle Biosciences CEO Derek Maetzold sells $462,567 in stock

On October 19, 2026, Derek J. Maetzold, the President and Chief Executive Officer of Castle Biosciences Inc. (CSTL), sold 14,496 shares of the company's common stock for a total value of $462,567. The sales took place at prices between $31.67 and $32.53 per share, with an average price of $31.91 per share. The Maetzold family controlled the transactions, with 8,580 shares sold directly by Mr. Maetzold, 3,198 shares sold indirectly through The Maetzold Descendants 2020 Trust (where his spouse serves as trustee and his spouse and children are beneficiaries), and 2,718 shares sold indirectly through the Derek Maetzold 2020 Irrevocable Trust (where he is the trustee and his children are beneficiaries).

These sales were executed under a Rule 10b5-1 trading plan that Maetzold adopted on June 2, 2026. Castle Biosciences stock has experienced a 35% increase over the past six months and a 42% rise over the past year, although it is currently considered overvalued based on InvestingPro data, trading at $34.37 compared to InvestingPro's Fair Value assessment of $30.15.

Following the insider sale, Mr. Maetzold directly owns 12,484 shares of Castle Biosciences common stock and still holds shares indirectly through various trusts.